nilotinib + imatinib (Novartis)

The entity identified as **o-Gruppo Italiano Malattie EMatologiche dell'Adulto-chronic myeloid leukemia** refers to the therapeutic agents and protocol evaluated in the **SUSTRENIM** (GIMEMA CLM1415) clinical trial. This Phase 4 study, sponsored by the Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA), compares the efficacy of frontline **nilotinib** (Tasigna) against **imatinib** (Gleevec/Glivec) in patients with newly diagnosed chronic phase BCR-ABL+ chronic myeloid leukemia (CP-CML). The trial design includes a strategic early switch from imatinib to nilotinib for patients who do not achieve an optimal molecular response according to European LeukemiaNet (ELN) criteria. Both nilotinib and imatinib are small molecule tyrosine kinase inhibitors (TKIs) that target the BCR-ABL1 fusion protein, the primary oncogenic driver of CML. The study's primary objectives are to achieve deep molecular response (DMR) and evaluate the potential for sustained treatment-free remission (TFR).

Brand names

TasignaGleevecGlivec

Other names

o-Gruppo Italiano Malattie EMatologiche dell'Adulto-chronic myeloid leukemiaNilotinibImatinibNilotinib versus Imatinib